ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD32B Monoclonal Antibody BI-1607

Its studies are mostly in Uveal Melanoma · Breast Neoplasms, led by BioInvent International AB.

Furthest: phase 2, since Sep 22, 20222 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioInvent International AB21 open or runningphase 2since Sep 22, 2022Sep 22, 2022none ahead

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2022First study: phase 2 study in HER2-positive Breast CancerFirst studyNCT05555251 · 18 enrolled · Germany, Spain, United Kingdom
  2. Dec 16, 2024Phase 2 study in MelanomaNCT06784648 · 35 enrolled · Germany, Spain, United Kingdom

TargetBeta

FCGR2B →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody targeting Fc gamma receptor IIB (FcgRIIB; CD32B), ”NCIt, by rule

Other programs on FCGR2B

ProgramCompanyFurthest phaseStudies
obexelimabzenas-biopharma-usa-llcphase 37

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06784648Melanoma · Germany, Spain, United Kingdom2Active, not recruitingSep 9, 202635
NCT05555251HER2-positive Breast Cancer · Germany, Spain, United Kingdom2TerminatedFeb 7, 202418

How it is read

Names in the registry

  • “BI-1607”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.